Literature DB >> 15077225

Racial diversity with high nucleated cell counts and CD34 counts achieved in a national network of cord blood banks.

Karen K Ballen1, Joanne Kurtzberg, Thomas A Lane, Bruce R Lindgren, John P Miller, Denis Nagan, Bruce Newman, Neil Rupp, N Rebecca Haley.   

Abstract

Banked, unrelated, partially HLA-matched, umbilical cord blood is an alternative stem cell source for patients in need of transplantation therapy who lack traditionally matched donors. A presumed advantage of cord blood is the ability to increase recruitment of donors of minority ethnic backgrounds. The American Red Cross Cord Blood Program was established in 1999 with 6 banks and 10 collection sites throughout the country. Cord blood donors self-report racial designations on questionnaires, and donor race was collected from each site. Postprocessing nucleated cell counts and CD34(+) counts were obtained on the cord blood units, and results from each racial group (white, black, Asian, Hispanic, and Native American) were compared in the natural logarithmic scale by using analysis of variance. A total of 18878 donors consented: 64% white, 16% black, 12% Hispanic, 4% Asian, 1% Native American, and 3% other. The Detroit area consented the highest percentage of black donors (87%), San Diego consented the highest percentage of Hispanic donors (59%), and Oakland consented the highest percentage of Asian donors (15%). Seven thousand eight hundred sixty-six cord blood units have been banked for transplantation. The mean preprocessing nucleated cell count was 1220 x 10(6) (range, 327-7300 x 10(6)). There was no difference among racial groups when controlled for site (P =.395). The mean CD34(+) count was 3.28 x 10(6). Blacks had a significantly lower CD34(+) count than the other racial/ethnic groups in the Midwest, Northwest, and North Carolina collection sites. A racially diverse cord blood bank can be achieved. Nucleated cell counts were similar among the different racial/ethnic groups. CD34(+) counts were lower for blacks in some collection sites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077225     DOI: 10.1016/j.bbmt.2003.12.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

1.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

2.  Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes.

Authors:  Karen K Ballen; John P Klein; Tanya L Pedersen; Deepika Bhatla; Reggie Duerst; Joanne Kurtzberg; Hillard M Lazarus; Charles F LeMaistre; Phillip McCarthy; Paulette Mehta; Jeanne Palmer; Michelle Setterholm; John R Wingard; Steven Joffe; Susan K Parsons; Galen E Switzer; Stephanie J Lee; J Douglas Rizzo; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-04       Impact factor: 5.742

Review 3.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

4.  Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait.

Authors:  Sandhya R Panch; Yu Ying Yau; Courtney D Fitzhugh; Matthew M Hsieh; John F Tisdale; Susan F Leitman
Journal:  Transfusion       Date:  2016-05       Impact factor: 3.157

5.  Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?

Authors:  Matthew M Hsieh; John F Tisdale; Griffin P Rodgers; Neal S Young; Edward L Trimble; Richard F Little
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Cord blood collection and banking from a population with highly diverse geographic origins increase HLA diversity in the registry and do not lower the proportion of validated cord blood units: experience of the Marseille Cord Blood Bank.

Authors:  C Bordoni; J Magalon; C Gilbertas; M Gamerre; P Le Coz; M Berthomieu; C Chabannon; J Di Cristofaro; C Picard
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 7.  Cellular immune therapy for refractory cancers: novel therapeutic strategies.

Authors:  Karen K Ballen; Gerald Colvin; Bimalangshu R Dey; David Porter; Peter Westervelt; Thomas R Spitzer; Peter J Quesenberry
Journal:  Exp Hematol       Date:  2005-12       Impact factor: 3.084

8.  Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality.

Authors:  Kristin M Page; Adam Mendizabal; Brigid Betz-Stablein; Stephen Wease; Kevin Shoulars; Tracy Gentry; Vinod K Prasad; Jessica Sun; Shelly Carter; Andrew E Balber; Joanne Kurtzberg
Journal:  Transfusion       Date:  2013-05-27       Impact factor: 3.157

9.  Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.

Authors:  Sumithira Vasu; Susan F Leitman; John F Tisdale; Matthew M Hsieh; Richard W Childs; A John Barrett; Daniel H Fowler; Michael R Bishop; Elizabeth M Kang; Harry L Malech; Cynthia E Dunbar; Hanh M Khuu; Robert Wesley; Yu Y Yau; Charles D Bolan
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

10.  Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.

Authors:  Joanne Kurtzberg; Vinod K Prasad; Shelly L Carter; John E Wagner; Lee Ann Baxter-Lowe; Donna Wall; Neena Kapoor; Eva C Guinan; Stephen A Feig; Elizabeth L Wagner; Nancy A Kernan
Journal:  Blood       Date:  2008-08-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.